← Back to guidelines
Cardiology31 papers

Hepatic porphyria

Last edited: 4/15/2026

Overview

Acute hepatic porphyrias (AHP) are rare genetic disorders affecting heme metabolism, including acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and 5-aminolevulinic acid dehydratase deficiency porphyria. These conditions primarily manifest as recurrent episodes of severe abdominal pain, often in women aged 15-50 years 1.

Diagnosis

  • Clinical Presentation: Recurrent severe abdominal pain without peritoneal signs or imaging abnormalities 1.
  • Screening Tests: Elevated urinary porphobilinogen and/or δ-aminolevulinic acid corrected to creatinine 1.
  • Initial Presumption: Elevations in urinary porphobilinogen and/or δ-aminolevulinic acid suggest AHP 1.
  • Management

  • Discontinue Porphyrinogenic Agents: Stop any drugs or chemicals known to trigger attacks 1.
  • Glucose Administration: Oral or intravenous dextrose to stabilize metabolic state 1.
  • Heme Therapy: Consideration of hemin therapy under specific clinical scenarios, though detailed dosing not provided in abstracts 2.
  • Special Populations

  • Pregnancy: Specific management considerations not detailed in provided abstracts 1.
  • Pediatrics: Management strategies for pediatric patients not addressed in abstracts 1.
  • Elderly: No specific guidance provided for elderly patients in the abstracts 1.
  • Comorbidities: Impact of comorbidities on management not discussed 1.
  • Key Recommendations

  • Consider AHP in Women Aged 15-50 with Recurrent Severe Abdominal Pain: Evaluate for AHP in this demographic, especially when common causes are excluded (Evidence: Expert opinion) 1.
  • Use Urinary Porphobilinogen and δ-Aminolevulinic Acid for Screening: Employ these biomarkers for initial screening of AHP (Evidence: Expert opinion) 1.
  • Discontinue Porphyrinogenic Drugs and Administer Glucose: Manage acute attacks by discontinuing triggering agents and providing glucose (Evidence: Expert opinion) 1.
  • References

    1 Wang B, Bonkovsky HL, Lim JK, Balwani M. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Gastroenterology 2023. link 2 Badawy AA. Multiple roles of haem in cystathionine β-synthase activity: implications for hemin and other therapies of acute hepatic porphyria. Bioscience reports 2021. link

    Original source

    1. [1]
      AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.Wang B, Bonkovsky HL, Lim JK, Balwani M Gastroenterology (2023)
    2. [2]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG